MLchartDataset catalogue

CR2-fH fusion protein TT30

Term · Oncology and biomedicine · MLC-T-ONC-012795

A recombinant, chimeric human fusion protein consisting of the iC3b/C3d-binding region of human complement receptor type 2 (CR2/CD21) linked to the alternative complement pathway (ACP) inhibitory domain of human factor H (fH) (CR2-fH), with potential complement system inhibiting activity. Via its C3 binding domain, TT30 selectively binds to complement activated cell surfaces and via its fH binding domain regulates ACP activity. This suppresses excessive complement activity and may result in an inhibition of ACP-mediated hemolysis of paroxysmal nocturnal hemoglobinuria (PNH) red blood cells (RBCs) as well as preventing ACP-induced tissue damage. Factor H is a key regulator in the activation of ACP.

Table 1. Record
IdentifierMLC-T-ONC-012795
FieldOncology and biomedicine
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-012795",
  "term": "CR2-fH fusion protein TT30",
  "field": "Oncology and biomedicine",
  "definition": "A recombinant, chimeric human fusion protein consisting of the iC3b/C3d-binding region of human complement receptor type 2 (CR2/CD21) linked to the alternative complement pathway (ACP) inhibitory domain of human factor H (fH) (CR2-fH), with potential complement system inhibiting activity. Via its C3 binding domain, TT30 selectively binds to complement activated cell surfaces and via its fH binding domain regulates ACP activity. This suppresses excessive complement activity and may result in an inhibition of ACP-mediated hemolysis of paroxysmal nocturnal hemoglobinuria (PNH) red blood cells (RBCs) as well as preventing ACP-induced tissue damage. Factor H is a key regulator in the activation of ACP.",
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/cr2-fh-fusion-protein-tt30/"
}

Record 5,408 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.